Publisher
Springer International Publishing
Reference85 articles.
1. Abdallah CG, Averill LA, Gueorguieva R et al (2018) Rapamycin, an immunosuppressant and mTORC1 inhibitor, triples the antidepressant response rate of ketamine at 2 weeks following treatment: a double-blind, placebo-controlled, cross-over, randomized clinical trial. bioRxiv:500959. https://doi.org/10.1101/500959
2. Aleksandrova LR, Phillips AG, Wang YT (2017) Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J Psychiatry Neurosci 42:222–229
3. Allergan (2019) Press release: allergan announces phase 3 results for rapastinel as an adjunctive treatment of major depressive disorder (MDD). Allergan Webpage. https://www.allergan.com/News/Details/2019/03/Allergan. Accessed 20 Feb 2020
4. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM–5)
5. Autry AE, Adachi M, Nosyreva E et al (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91–96. https://doi.org/10.1038/nature10130